Ruxolitinib for Steroid-Refractory Acute GVHD: An Interview With Corey S. Cutler, MD, MPH, FRCPC

Recently, the FDA approved ruxolitinib (Jakafi®, Incyte Corporation), a JAK1/JAK2 inhibitor, for the treatment of steroid-refractory acute graft-versus-host disease (GVHD). A potentially life-threatening condition, GVHD is a complication of allogeneic hematopoietic stem cell transplantation (HSCT), a treatment for hematologic malignancies that is administered following high-intensity chemotherapy or radiation. In this interview with i3 Health, Corey S. Cutler, MD, MPH, FRCPC, Medical Director of...
Continue reading

Polatuzumab Vedotin Approved in Relapsed/Refractory DLBCL

The FDA has now granted accelerated approval to polatuzumab vedotin (Polivy®, Genentech, Inc.) in combination with bendamustine and a rituximab product for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, following two or more prior lines of therapy. Estimates of five-year survival for DLBCL have been reported at 62.0% in the United States and 55.4% in Europe. Over 50% of patients with advanced-stage, previously untreated DLBCL experience complet...
Continue reading

Rituximab/Lenalidomide/Ibrutinib Effective in DLBCL

A phase 2 study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting revealed that a combination of rituximab (Rituxan®, Genentech USA, Inc), lenalidomide (Revlimid®, Celgene Corporation), and ibrutinib (Imbruvica®, Janssen Biotech, Inc) demonstrates overall response in adult patients with previously untreated non-germinal center B-cell (non-GCB)–like subtype diffuse large B-cell lymphoma (DLBCL). Rituximab, which targets abnormal B cells and reduces their lifespan, is al...
Continue reading

Lenalidomide/Rituximab for Follicular Lymphoma and Marginal Zone Lymphoma: John P. Leonard, MD

This week, the FDA approved lenalidomide (Revlimid®, Celgene Corporation) in combination with a rituximab product for relapsed/refractory follicular lymphoma (FL) and relapsed/refractory marginal zone lymphoma (MZL). In this interview with i3 Health, John P. Leonard, MD, lead author of the AUGMENT trial, on which the approval was based, discusses the approval's importance and shares his advice for physicians treating patients with relapsed/refractory FL or MZL. Can you comment on the significanc...
Continue reading

Acute Myeloid Leukemia: OS Data Approved for Gilteritinib

The FDA has now approved the addition of data on overall survival (OS) to the labeling of gilteritinib (Xospata®, Astellas Pharma US, Inc.), which is indicated for adults with previously treated acute myeloid leukemia (AML) with an FLT3 mutation. These new data demonstrate that gilteritinib has been successful in increasing OS. One of the types of leukemia occurring most frequently in adults, AML is still fairly rare, representing around 1% of all cancers. According to American Cancer Society es...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.